274 related articles for article (PubMed ID: 33220180)
1. Normal Somatic Mutations in Cancer Transformation.
Wijewardhane N; Dressler L; Ciccarelli FD
Cancer Cell; 2021 Feb; 39(2):125-129. PubMed ID: 33220180
[TBL] [Abstract][Full Text] [Related]
2. Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer.
Gatenby RA; Brown J
Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):162-166. PubMed ID: 28341421
[TBL] [Abstract][Full Text] [Related]
3. The Long Evolutionary Journey of Cancer from Ancestor to Modern Humans.
Carruba G; Trosko JE
Crit Rev Oncog; 2017; 22(3-4):323-352. PubMed ID: 29604908
[TBL] [Abstract][Full Text] [Related]
4. [Tumor suppressor gene p53. Theoretical principles and their significance for pathology].
Poremba C; Bankfalvi A; Dockhorn-Dworniczak B
Pathologe; 1996 May; 17(3):181-8. PubMed ID: 8710788
[TBL] [Abstract][Full Text] [Related]
5. Cell Competition in Carcinogenesis.
Madan E; Palma AM; Vudatha V; Trevino JG; Natarajan KN; Winn RA; Won KJ; Graham TA; Drapkin R; McDonald SAC; Fisher PB; Gogna R
Cancer Res; 2022 Dec; 82(24):4487-4496. PubMed ID: 36214625
[TBL] [Abstract][Full Text] [Related]
6. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets.
Zhang S; Xiao X; Yi Y; Wang X; Zhu L; Shen Y; Lin D; Wu C
Signal Transduct Target Ther; 2024 Jun; 9(1):149. PubMed ID: 38890350
[TBL] [Abstract][Full Text] [Related]
7. Stochastic gene expression, disruption of tissue averaging effects and cancer as a disease of development.
Capp JP
Bioessays; 2005 Dec; 27(12):1277-85. PubMed ID: 16299757
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneity generating capacity in tumorigenesis and cancer therapeutics.
Lenz G
Biochim Biophys Acta Mol Basis Dis; 2024 Jun; 1870(5):167226. PubMed ID: 38734320
[TBL] [Abstract][Full Text] [Related]
9. A step-by-step microRNA guide to cancer development and metastasis.
Markopoulos GS; Roupakia E; Tokamani M; Chavdoula E; Hatziapostolou M; Polytarchou C; Marcu KB; Papavassiliou AG; Sandaltzopoulos R; Kolettas E
Cell Oncol (Dordr); 2017 Aug; 40(4):303-339. PubMed ID: 28748501
[TBL] [Abstract][Full Text] [Related]
10. Genomic instability en route to and from cancer stem cells.
Li L; Borodyansky L; Yang Y
Cell Cycle; 2009 Apr; 8(7):1000-2. PubMed ID: 19270518
[TBL] [Abstract][Full Text] [Related]
11. Field Carcinogenesis in Cancer Evolution: What the Cell Is Going On?
Sinjab A; Han G; Wang L; Kadara H
Cancer Res; 2020 Nov; 80(22):4888-4891. PubMed ID: 33023945
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics: surveillance team against cancer.
Klein G
Nature; 2005 Mar; 434(7030):150. PubMed ID: 15758980
[No Abstract] [Full Text] [Related]
13. Tissue disruption increases stochastic gene expression thus producing tumors: Cancer initiation without driver mutation.
Capp JP
Int J Cancer; 2017 Jun; 140(11):2408-2413. PubMed ID: 28052327
[TBL] [Abstract][Full Text] [Related]
14. The epigenomics of cancer.
Jones PA; Baylin SB
Cell; 2007 Feb; 128(4):683-92. PubMed ID: 17320506
[TBL] [Abstract][Full Text] [Related]
15.
Colebatch AJ; Dobrovic A; Cooper WA
J Clin Pathol; 2019 Apr; 72(4):281-284. PubMed ID: 30696697
[TBL] [Abstract][Full Text] [Related]
16. The mini-driver model of polygenic cancer evolution.
Castro-Giner F; Ratcliffe P; Tomlinson I
Nat Rev Cancer; 2015 Nov; 15(11):680-5. PubMed ID: 26456849
[TBL] [Abstract][Full Text] [Related]
17. The temporal order of genetic and pathway alterations in tumorigenesis.
Gerstung M; Eriksson N; Lin J; Vogelstein B; Beerenwinkel N
PLoS One; 2011; 6(11):e27136. PubMed ID: 22069497
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of oncogenic cell competition-Paths of victory.
Gutiérrez-Martínez A; Sew WQG; Molano-Fernández M; Carretero-Junquera M; Herranz H
Semin Cancer Biol; 2020 Jun; 63():27-35. PubMed ID: 31128299
[TBL] [Abstract][Full Text] [Related]
19. DNA repair in cancer initiation, progression, and therapy-a double-edged sword.
Kiwerska K; Szyfter K
J Appl Genet; 2019 Nov; 60(3-4):329-334. PubMed ID: 31468363
[TBL] [Abstract][Full Text] [Related]
20. Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis.
Josson S; Gururajan M; Sung SY; Hu P; Shao C; Zhau HE; Liu C; Lichterman J; Duan P; Li Q; Rogatko A; Posadas EM; Haga CL; Chung LW
Oncogene; 2015 May; 34(21):2690-9. PubMed ID: 25065597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
